{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-26-000050","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2026-06-16T20:02:56+00:00","discovered_at":"2026-06-16T20:04:00.671434+00:00","generated_at":"2026-06-16T20:04:53.459107+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Arrowhead appoints Dr. Matt Cohen to board of directors","bullets":["Appointed Dr. Matt Cohen, M.D., M.B.A., as director effective June 12, 2026.","Cohen is Managing Director at Vida Ventures; previously lead healthcare investor at JPMorgan for ~20 years.","Received standard non-employee director compensation plus sign-on RSU grant of $887,000 vesting over three years.","No family relationships or arrangements with any other director or officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-26-000050","json":"https://secwatch.observer/filing/0000879407-26-000050.json","markdown":"https://secwatch.observer/filing/0000879407-26-000050.md","text":"https://secwatch.observer/filing/0000879407-26-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/0000879407-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/arwr-20260612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T20:04:53.459107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"596303a3fa","claim":"Dr. Matt Cohen was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..","evidence_excerpt":"On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/0000879407-26-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}